Peter McCullough
Cardiovascular Disease · Dallas, TXNPI 1386604700
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 22.0%. Reporting peaked in 2019 at $362,280 and has fallen 100.0% since, to $21 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 679 payments — averaging $977.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$146K
- Sanofi-aventis U.S. LLC$107K
- Amgen$44K
- Novo Nordisk AS$40K
- Bayer$36K
- Merck$33K
- plus $258K from 46 others
Across 426 payments — averaging $1114.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$123K
- Boehringer Ingelheim International GmbH$104K
- Amgen$90K
- Novo Nordisk AS$47K
- Boehringer Ingelheim Pharma GmbH & Co.kg$37K
- Novartis$27K
- plus $46K from 5 others
What the payments were for
- Consulting fees$388,07058%
- Speaking & faculty fees$198,08030%
- Travel & lodging$68,66610%
- Food & beverage$8,9141%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$61,172
- JARDIANCE$47,750
- FARXIGA$45,594
- PRALUENT$40,866
- Non-Covered$33,711
- STEGLATRO$32,093
- Repatha$31,308
- Victoza$24,533
- AURYXIA$17,980
- GZ402671$17,078
- EVENITY$13,904
- System One$11,378
- XARELTO$10,000
- INVOKANA$6,314
- Renal - PD$5,902
- NXSTAGE SYSTEM ONE$5,350
- Prolia$5,104
- ACTHAR$3,707
- TRIFERIC$3,000
- CardioMEMS HF System$2,400
How this compares
$663,775 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 26 | $43,648 |
| VerquvoVericiguat | 29 | $30,478 |
| Repatha SureclickEvolocumab | 24 | $26,283 |
| JardianceEmpagliflozin | 18 | $19,482 |
| FarxigaDapagliflozin Propanediol | 23 | $17,550 |
| EliquisApixaban | 13 | $16,696 |
| Repatha PushtronexEvolocumab | 13 | $13,605 |
| MounjaroTirzepatide | 13 | $11,922 |
| Colchicine | 56 | $3,289 |
| Ezetimibe | 83 | $2,537 |
| Ramipril | 111 | $1,826 |
| Bisoprolol Fumarate | 53 | $1,368 |
| Rosuvastatin Calcium | 70 | $1,137 |
| Chlorthalidone | 34 | $668 |
| Np ThyroidThyroid,pork | 11 | $664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $269 | $43,64826 claims |
| MerckVerquvo | $32,712 | $30,47829 claims |
| Boehringer IngelheimJardiance | $14,071 | $19,48218 claims |
| AstraZenecaFarxiga | $145,994 | $17,55023 claims |
| Lilly USA, LLCMounjaro | $15,336 | $11,92213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Dallas
- Ramin Farzaneh-FarDallas$17.1M
- Darren McGuireDallas$1.2M
- Ann NavarDallas$616K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Ambarish PandeyDallas$325K
- Eric PetersonDallas$187K
- Brittany WeberDallas$186K
- James de LemosDallas$181K
- Subhash BanerjeeDallas$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.